NVA237 (umeclidinium)

umeclidinium · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NVA237 (umeclidinium), covering 2012-05-07 to 2012-05-07. Get the full timeline:

Most recent: Clinical Trial Update: Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]